Publications by authors named "S D Edland"

Background: Benfotiamine, a prodrug of thiamine, raises blood levels by 50-100 times to achieve pharmacologic effects. It provides a novel therapeutic direction addressing a well-characterized brain tissue thiamine deficiency and related changes in glucose metabolism in AD. BenfoTeam is a seamless phase 2A-2B "proof of concept" (POC), double-blind, placebo-controlled RCT investigating tolerability, safety, and efficacy of benfotiamine, as a first-in-class small molecule treatment for early AD.

View Article and Find Full Text PDF

Introduction: Identifying low-cost, minimally-invasive screening instruments for Alzheimer's disease (AD) trial enrichment will improve the efficiency of AD trials.

Methods: A total of 685 cognitively normal (CN) individuals and individuals with mild cognitive impairment (MCI) from the Alzheimer's Disease Neuroimaging Initiative (ADNI) were grouped according to cutoffs of genetic risk factor (G) polygenic hazard score (PHS) and tau pathology (T) plasma phosphorylated tau-181 (p-tau181) into four groups: G+T+, G-T-, G+T-, and G-T+. We assessed the associations between group level and longitudinal cognitive decline and AD conversion.

View Article and Find Full Text PDF

Impaired episodic memory is the primary feature of early Alzheimer's disease (AD), but not all memories are equally affected. Patients with AD and amnestic Mild Cognitive Impairment (aMCI) remember pictures better than words, to a greater extent than healthy elderly. We investigated neural mechanisms for visual object recognition in 30 patients (14 AD, 16 aMCI) and 36 cognitively unimpaired healthy (19 in the "preclinical" stage of AD).

View Article and Find Full Text PDF

High-density lipoprotein (HDL) is protective against cardiovascular disease. Exercise can increase HDL concentration, and some evidence suggests that this effect occurs more strongly in women than in men. Both HDL and exercise are associated with inflammation.

View Article and Find Full Text PDF
Article Synopsis
  • Benfotiamine is being tested as a new oral treatment option for early Alzheimer's disease (AD), potentially enhancing the effects of existing therapies targeting amyloid.
  • A 72-week randomized, double-blind, placebo-controlled trial will investigate its safety, tolerability, and efficacy in 406 participants, starting with a phase 2A to find the optimal dose before moving to phase 2B.
  • The trial's innovative design allows for a smooth transition between phases, aiming to confirm benefits through specific cognitive and safety assessments.
View Article and Find Full Text PDF